HEOR (Health Economics and Outcomes Research)

Health Economics and Outcomes Research (HEOR) is a multidisciplinary field that evaluates the clinical, economic, and humanistic outcomes of health care interventions to inform decision making about resource allocation, pricing, reimbursement, and health policy. HEOR integrates methods from economics, epidemiology, biostatistics, outcomes research, and decision science to assess the value of treatments, devices, diagnostics, and health care delivery models.

Health care resources are finite, and not every effective intervention can be funded. HEOR provides the analytical framework for determining which interventions deliver the most value relative to their cost, enabling health systems, payers, and policymakers to make informed allocation decisions. Health technology assessment (HTA) bodies in countries around the world (such as NICE in England, Canada's Drug Agency, formerly CADTH, and PBAC in Australia) rely on HEOR evidence to make or advise on coverage and reimbursement decisions; in Germany, IQWiG assesses a new drug's added benefit for the Federal Joint Committee (G-BA), which decides on it. Regulators answer a different question: in the United States the FDA, and in the European Union the European Commission on the advice of the EMA, authorize medicines on evidence of quality, safety and efficacy, not cost, so HEOR evidence matters mainly to the payers and HTA bodies that decide or advise on coverage, reimbursement and price. Pharmaceutical and medical device companies use HEOR to demonstrate the value of their products beyond clinical efficacy. For patients, HEOR evidence influences which treatments are available and affordable. As health care costs rise globally, the role of HEOR in ensuring that spending achieves the greatest possible health benefit becomes increasingly important.

HEOR encompasses several interrelated methodologies. Cost effectiveness analysis (CEA) compares the costs and health outcomes of alternative interventions, expressed as a cost per unit of health gained, such as the cost per life year gained. Cost utility analysis is the form of CEA that uses quality adjusted life years (QALYs) as the outcome measure, incorporating both length and quality of life, and reports the cost per QALY gained. Cost benefit analysis assigns monetary values to all outcomes (including health outcomes) and compares total costs with total benefits. Budget impact analysis estimates the financial consequences of adopting a new intervention within a specific health care system over a defined time horizon.

Patient reported outcomes (PROs) capture the patient's perspective on their health status, symptoms, functioning, and quality of life. PRO instruments (such as the EQ 5D for health utilities or the SF 36 for health related quality of life) are used in clinical trials and observational studies to generate the outcomes data that feed into HEOR analyses.

Real world evidence (RWE), derived from the analysis of real world data such as electronic health records, claims databases, and registries, complements clinical trial data by providing evidence about how interventions perform in routine clinical practice, in broader patient populations, and over longer time horizons.

Decision modeling (including decision trees, Markov models, discrete event simulation, and microsimulation) synthesizes evidence from multiple sources to estimate the long term costs and outcomes of alternative treatment strategies. Sensitivity analyses explore how the conclusions change under different assumptions about key parameters.

HEOR is used throughout the product lifecycle: during early development (to inform go or no go decisions and pricing strategy), during clinical trials (to collect economic and outcomes data), at the time of market access (to support reimbursement submissions to HTA bodies), and post launch (to generate real world evidence of value). It is relevant to pharmaceutical and device manufacturers, health system planners, payers, guideline developers, and policymakers. Researchers pursuing careers in health economics, outcomes research, or health technology assessment need training in HEOR methods.

A common error is confusing cost effectiveness with cost saving. An intervention that is cost effective delivers health benefits at an acceptable cost per QALY, but it may still increase total spending. Another mistake is using clinical trial data directly in economic models without adjusting for the artificial conditions of the trial (such as protocol driven monitoring and adherence support) that may not reflect real world practice. Failing to conduct sensitivity analyses to test the stability of the model's conclusions is another common deficiency. Some HEOR analyses use inappropriately short time horizons, missing important long term costs or benefits (such as the lifetime costs averted by preventing a chronic condition). Finally, not clearly reporting the perspective of the analysis (societal, health care system, or payer) can lead to misinterpretation of the results, since the included costs and outcomes differ by perspective.

In a hypothetical example, a pharmaceutical company submits a cost effectiveness analysis of a new hepatitis C treatment to a national HTA body. The analysis uses a Markov model with a lifetime horizon and a health care system perspective. The model estimates that treating a cohort of 10,000 patients with the new drug (at $50,000 per treatment course) compared with the standard treatment ($30,000 per course) would prevent 850 cases of cirrhosis, 280 cases of liver cancer, and 190 liver related deaths in the first 20 years of the projection. The incremental cost effectiveness ratio is $28,500 per QALY gained, which falls below the country's willingness to pay threshold of $50,000 per QALY. Sensitivity analysis confirms that the result is stable across plausible ranges of cure rate (90% to 98%), discount rate (1.5% to 5%), and disease progression probabilities. The HTA body recommends reimbursement.